Logo image of MDXH

MDXHEALTH (MDXH) Stock Price, Quote, News and Overview

NASDAQ:MDXH - Nasdaq - BE0974461940 - Common Stock - Currency: USD

1.86  0 (0%)

MDXH Quote, Performance and Key Statistics

MDXHEALTH

NASDAQ:MDXH (2/21/2025, 8:00:01 PM)

1.86

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.85
52 Week Low1.55
Market Cap50.76M
Shares27.29M
Float23.95M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2025-02-26/amc
IPO06-26 2006-06-26


MDXH short term performance overview.The bars show the price performance of MDXH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

MDXH long term performance overview.The bars show the price performance of MDXH in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of MDXH is 1.86 USD. In the past month the price decreased by -6.53%. In the past year, price decreased by -47.9%.

MDXHEALTH / MDXH Daily stock chart

MDXH Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About MDXH

Company Profile

MDXH logo image MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege and currently employs 300 full-time employees. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Company Info

MDXHEALTH

CAP Business Center, Rue d'Abhooz 31

Herstal LIEGE BE

Employees: 300

Company Website: https://mdxhealth.com/

Investor Relations: https://mdxhealth.com/investors/

Phone: 3243642070

MDXHEALTH / MDXH FAQ

What is the stock price of MDXHEALTH today?

The current stock price of MDXH is 1.86 USD.


What is the ticker symbol for MDXHEALTH stock?

The exchange symbol of MDXHEALTH is MDXH and it is listed on the Nasdaq exchange.


On which exchange is MDXH stock listed?

MDXH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MDXHEALTH stock?

12 analysts have analysed MDXH and the average price target is 6.16 USD. This implies a price increase of 231.23% is expected in the next year compared to the current price of 1.86. Check the MDXHEALTH stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MDXHEALTH worth?

MDXHEALTH (MDXH) has a market capitalization of 50.76M USD. This makes MDXH a Micro Cap stock.


How many employees does MDXHEALTH have?

MDXHEALTH (MDXH) currently has 300 employees.


What are the support and resistance levels for MDXHEALTH (MDXH) stock?

MDXHEALTH (MDXH) has a support level at 1.85 and a resistance level at 1.87. Check the full technical report for a detailed analysis of MDXH support and resistance levels.


Is MDXHEALTH (MDXH) expected to grow?

The Revenue of MDXHEALTH (MDXH) is expected to grow by 27.93% in the next year. Check the estimates tab for more information on the MDXH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MDXHEALTH (MDXH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MDXHEALTH (MDXH) stock pay dividends?

MDXH does not pay a dividend.


When does MDXHEALTH (MDXH) report earnings?

MDXHEALTH (MDXH) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of MDXHEALTH (MDXH)?

MDXHEALTH (MDXH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).


What is the Short Interest ratio of MDXHEALTH (MDXH) stock?

The outstanding short interest for MDXHEALTH (MDXH) is 0.07% of its float. Check the ownership tab for more information on the MDXH short interest.


MDXH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MDXH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MDXH. MDXH may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDXH Financial Highlights

Over the last trailing twelve months MDXH reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 33.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.37%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%20.5%
EPS 1Y (TTM)33.91%
Revenue 1Y (TTM)89.45%

MDXH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to MDXH. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 22.81% and a revenue growth 27.93% for MDXH


Ownership
Inst Owners31.09%
Ins Owners1.52%
Short Float %0.07%
Short Ratio0.16
Analysts
Analysts86.67
Price Target6.16 (231.18%)
EPS Next Y22.81%
Revenue Next Year27.93%